BiotechTube

Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + Sevoflurane

ApprovedUNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Post-operative Residual Curarization

Conditions

Post-operative Residual Curarization

Trial Timeline

Nov 1, 2014 → Jul 1, 2017

NCT ID
NCT02698969

About Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + Sevoflurane

Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + Sevoflurane is a approved stage product being developed by Merck for Post-operative Residual Curarization. The current trial status is unknown. This product is registered under clinical trial identifier NCT02698969. Target conditions include Post-operative Residual Curarization.

What happened to similar drugs?

3 of 11 similar drugs in Post-operative Residual Curarization were approved

Approved (3) Terminated (0) Active (8)
✅granisetron + granisetronRocheApproved
✅Parecoxib SodiumPfizerApproved
✅RopivacaineLundbeckApproved
🔄Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
🔄Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
🔄Comparator: MK0517 + Comparator: ondansetronMerckPhase 3
🔄lyricaPfizerPhase 3

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02698969ApprovedUNKNOWN

Competing Products

18 competing products in Post-operative Residual Curarization

See all competitors
ProductCompanyStageHype Score
QutenzaAstellas PharmaPre-clinical
26
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
40
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
40
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
38
AGN-151607 + PlaceboAbbViePhase 2
35
Comparator: MK0517 + Comparator: ondansetronMerckPhase 3
40
Aprepitant + Placebo to Aprepitant + Ondansetron + Placebo to match ondansetronMerckPhase 2
35
granisetron + granisetronRocheApproved
43
Parecoxib SodiumPfizerApproved
43
lyricaPfizerPhase 3
40
Placebo + Pregabalin + PregabalinPfizerPhase 1
29
Methylnaltrexone + PlaceboPfizerPhase 3
40
HSK16149 capsule + PlaceboHaisco Pharmaceutical GroupPhase 2
35
RopivacaineLundbeckApproved
40
Bupivacaine HCI without epinephrine + HTX-011Heron TherapeuticsPhase 2
25
Sufentanil NanoTab PCA System/15 mcg + morphine IV PCATalpheraPhase 3
30
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA SystemTalpheraPhase 3
30
Sufentanil Tablet 30 mcg + Placebo TabletTalpheraPhase 3
30